Free Trial
NASDAQ:SKYE

Skye Bioscience Q3 2026 Earnings Results & Report

Skye Bioscience logo
$1.09 0.00 (0.00%)
Closing price 11/13/2026 04:00 PM Eastern
Extended Trading
$1.16 +0.07 (+6.06%)
As of 11/13/2026 07:52 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Skye Bioscience reported Q3 2026 earnings on November 13, 2026. The company reported EPS of $0.01.

Earnings Announcement Details

Quarter
Q3 2026
Time
After Market Closes
Conference Call Date
Conference Call
4:30 PM ET

Skye Bioscience EPS Results

Actual EPS
$0.01
Consensus EPS
N/A
Beat/Miss
N/A
One Year Ago EPS
N/A
EPS Beat Rate
4 of last 8 quarters

Skye Bioscience Revenue Results

Actual Revenue
N/A
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

Earnings Documents

Skye Bioscience Q3 2026 Earnings FAQ

Skye Bioscience (NASDAQ:SKYE) reported earnings of $0.01 per share for Q3 2026. The report was announced on Friday, November 13, 2026.

Skye Bioscience Earnings Headlines

Skye Bioscience (NASDAQ:SKYE) Stock Price Down 4.8% - Here's Why
What the hell is going on?
Porter Stansberry says President Trump is quietly replacing the U.S. dollar without a vote in Congress, and the shift is already underway. The dollar has lost 88% of its purchasing power since it was untethered from gold, and Fortune calls the current change the biggest shift in the world's relationship with the dollar in a generation. Stansberry says a similar reset is planned to be unveiled in Miami as soon as this December. Watch Porter Stansberry's full broadcast to see which companies could be affected.tc pixel
See More Skye Bioscience Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Skye Bioscience? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Skye Bioscience and other key companies, straight to your email.

About Skye Bioscience

Skye Bioscience (NASDAQ:SKYE) is a clinical-stage biopharmaceutical company developing medicines that target the endocannabinoid system. Its research focuses on cannabinoid receptor 1 (CB1), which is involved in metabolic and other physiological processes.

The company’s lead program is nimacimab, an antibody designed to inhibit CB1 activity outside the brain. Skye is investigating the candidate as a potential treatment for obesity and related metabolic conditions.

Skye has also developed SBI-100 ophthalmic emulsion, an experimental eye treatment studied for glaucoma and ocular hypertension. The company is based in San Diego, California, and has shifted its development focus toward nimacimab.

View Skye Bioscience Profile